EXAGEN INC. (XGN): $16.62

-0.80 (-4.59%)

POWR Rating

Component Grades













Filter XGN News Items

XGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

XGN News Highlights

  • XGN's 30 day story count now stands at 17.
  • Over the past 24 days, XGN's stories per day has been in a clear downtrend, falling by about -0.82 per 4 days.
  • The most mentioned tickers in articles about XGN are CB, SAFE and BIO.

Latest XGN News From Around the Web

Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.

Wasatch Advisors increased stake in Exagen Inc.


Investing.com | April 9, 2021

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus. The longitudinal study will further evaluate the emergence of biomarkers that are known indicators for the development of lupus, rheumatoid arthritis and other autoimmune diseases. This effort will assess the emergence of these biomarkers in mild/moderate COVID patients, among several critical patient groups, includi...

Yahoo | March 29, 2021

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million. Exagen intends to use the net proceeds from the proposed offering for the development of Multi-omics capabilities, including build out of its clinical laboratory, advancement of its product pipeline, incl...

Yahoo | March 25, 2021

Exagen raises $60M via equity offering

Exagen (XGN) has priced its public offering of 3.7M common shares at $16.25/share, for expected gross proceeds of $60.1M.Underwriters' over-allotment is an additional 555K shares. Net proceeds will be used for build out of clinical laboratory, advancement of its product pipeline, for working capital and other general corporate purposes.Closing date...

Seeking Alpha | March 23, 2021

AnPac Bio-Medical Science (NASDAQ:ANPC) vs. Exagen (NASDAQ:XGN) Head to Head Contrast

Exagen (NASDAQ:XGN) and AnPac Bio-Medical Science (NASDAQ:ANPC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Exagen and AnPac […]

Modern Readers | March 19, 2021

Exagen Inc. (XGN) CEO Ron Rocca on Q4 2020 Results - Earnings Call Transcript

Exagen Inc. (XGN) Q4 2020 Results Earnings Conference Call March 16, 2021, 4:30 9m ET Company Participants Mike Cavanaugh - Investor Relations, Managing Director at Westwicke Partners Ron Rocca - President, Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - Chief Operating Officer Conference Call Participants Chris...

SA Transcripts on Seeking Alpha | March 17, 2021

Exagen (NASDAQ:XGN) Posts Earnings Results, Beats Expectations By $0.13 EPS

Exagen (NASDAQ:XGN) posted its quarterly earnings data on Monday. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.13, MarketWatch Earnings reports. Exagen had a negative net margin of 39.49% and a negative return on equity of 29.10%. Shares of XGN opened at $20.30 on Wednesday. The […]

Transcript Daily | March 17, 2021

Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS

Exagen (NASDAQ:XGN) issued its quarterly earnings data on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.13, MarketWatch Earnings reports. Exagen had a negative net margin of 39.49% and a negative return on equity of 29.10%. Shares of NASDAQ XGN opened at […]

Daily Political | March 17, 2021

Exagen Inc. (XGN) Q4 2020 Earnings Call Transcript

Earlier today, Exagen Inc. released financial results for the quarter and fiscal year ended December 31, 2020. Ron Rocca, president and chief executive officer; Kamal Adawi, chief financial officer; and Mark Hazeltine, chief operating officer, will host this afternoon's call.

Yahoo | March 17, 2021

Exagen Earnings and Growth Analysis : Stock market Insights & financial analysis

Exagen announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 16, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6824 seconds.